# An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

> **NCT02667587** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 716 (actual)

## Conditions studied

- Brain Neoplasms

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Temozolomide
- **RADIATION:** Radiotherapy
- **OTHER:** Nivolumab Placebo

## Key facts

- **NCT ID:** NCT02667587
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-09
- **Primary completion:** 2020-12-22
- **Final completion:** 2024-04-09
- **Target enrollment:** 716 (ACTUAL)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02667587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02667587, "An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02667587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*